E Dilip De Silva

Title: E Dilip De Silva: Innovator in Antimitotic Compounds

Introduction

E Dilip De Silva is a notable inventor based in Vancouver, Canada. He has made significant contributions to the field of medicinal chemistry, particularly in the development of antimitotic compounds. With a total of 2 patents, his work has implications for drug formulation and delivery.

Latest Patents

One of his latest patents is focused on antimitotic eleuthesides. This invention provides analogs of eleutherobin and the eleuthesides modified at the C-11 position or comprising an epoxide functionality from C-11 to C-12. The C-11 to C-12 region is an ideal location for conjugating functional moieties to the eleutherobin pharmacophore without significant loss of antimitotic activity. Moieties that may be conjugated at C-11 include those intended to increase the solubility of the pharmacophore, facilitate drug formulation, or enhance in vivo delivery or targeting. Another significant patent involves a biologically active thiazine, specifically 5-Methylimidazo[4,5-e]-1,2-thiazin-4(5-H)-one. This compound, a cytotoxic metabolite of the marine sponge Neamphius huxleyi, has been isolated from the sponge through extraction and chromatography.

Career Highlights

E Dilip De Silva has worked with prestigious institutions such as the University of British Columbia and Cornell Research Foundation Inc. His research has focused on innovative approaches to drug development, particularly in the area of cancer treatment.

Collaborations

He has collaborated with notable individuals in his field, including Raymond John Andersen and Michel Roberge. These collaborations have contributed to the advancement of his research and the successful development of his patents.

Conclusion

E Dilip De Silva's contributions to medicinal chemistry and his innovative patents highlight his role as a significant inventor in the field. His work continues to influence drug development and therapeutic applications.